AC Immune and the Swiss Federal Institute of Technology Lausanne researchers have unveiled a class of small molecules that block amyloid fibril growth in AD. If the compounds can be made to enter the brain, the approach could arrest the growth of amyloid plaques upstream of the usual target points for antibodies.